论文部分内容阅读
目的:探讨索利那新对输尿管支架置入患者相关症状及生活质量的影响。方法:136例输尿管支架置入患者,按随机数字表法分成两组:试验组(n=68)给予索利那新5mg,1次/d,口服4周;对照组(n=68)未给予干预治疗,4周后通过输尿管支架置入相关症状评分表(USSQ)进行问卷调查。包括下尿路症状评分、支架置入相关疼痛评分、一般健康指数、工作能力评分和性生活指数等。结果:试验组和对照组USSQ中下尿路症状评分分别为(10.15±4.20)和(18.50±7.91),支架置入相关疼痛评分分别为(3.21±1.58)和(8.17±2.01),一般健康指数分别为(14.81±3.23)和(10.78±2.24),工作能力评分分别为(13.58±2.00)和(8.91±2.45),组间差异均有统计学意义(P<0.05)。性生活指数分别为(3.82±1.10)和(3.53±0.9),差异无统计学意义(P>0.05)。结论:索利那新能明显改善留置输尿管支架患者支架置入相关症状及生活质量。
Objective: To investigate the effects of solifenacin on the symptoms and quality of life of patients undergoing ureteral stenting. Methods: One hundred and sixty-six patients with ureteral stenting were divided into two groups according to the random number table: the experimental group (n = 68) received solifenacin 5 mg once daily for 4 weeks; the control group (n = 68) After 4 weeks of intervention, the urethral stent was put into the relevant symptom score (USSQ) questionnaire. Including the lower urinary tract symptom score, stent-related pain score, general health index, work ability score and sexual life index. Results: The scores of lower and middle urinary tract symptoms in the test group and the control group were (10.15 ± 4.20) and (18.50 ± 7.91), respectively, and the pain scores of stent placement were (3.21 ± 1.58) and (8.17 ± 2.01) (14.81 ± 3.23) and (10.78 ± 2.24) respectively, and the working ability scores were (13.58 ± 2.00) and (8.91 ± 2.45) respectively. The differences among the groups were statistically significant (P <0.05). Sexual life index were (3.82 ± 1.10) and (3.53 ± 0.9) respectively, with no significant difference (P> 0.05). Conclusion: Solifenac can significantly improve the placement-related symptoms and quality of life of patients with indwelling ureteral stents.